source
- Roivant's mosliciguat shows strong efficacy in Phase 2 PH-ILD trialRoivant's experimental drug mosliciguat achieved strong efficacy signals in a Phase 2 study of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The mid-stage trial met its…
- FDA places partial hold on Biohaven epilepsy drug BHV-7000 amid $350 million licensing dealThe U.S. Food and Drug Administration issued a partial clinical hold on enrollment for Biohaven’s epilepsy candidate BHV-7000 after rodent studies raised questions about drug metabolites. The hold…